Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - memantiin - õhukese polümeerikattega tablett - 20mg 20tk; 20mg 70tk; 20mg 60tk; 20mg 96tk; 20mg 18tk; 20mg 30tk; 20mg 98tk; 20mg 28tk; 20mg 7tk; 20mg 10tk; 20mg 40tk; 20mg 45tk; 20mg 84tk; 20mg 42tk; 20mg 48tk; 20mg 50tk; 20mg 100tk; 20mg 14tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - esetimiib - tablett - 10mg 7tk; 10mg 14tk; 10mg 90tk; 10mg 60tk; 10mg 28tk; 10mg 20tk; 10mg 50tk; 10mg 10tk; 10mg 98tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - metotreksaat - infusioonilahuse kontsentraat - 100mg 1ml 5ml 5tk; 100mg 1ml 10ml 1tk; 100mg 1ml 5ml 1tk; 100mg 1ml 50ml 5tk; 100mg 1ml 10ml 5tk

Eesti - eesti - Ravimiamet

chiesi pharmaceuticals gmbh - piroksikaam - suukaudse lahuse pulber - 20mg 20tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 10mg+10mg 10tk; 10mg+10mg 28tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 20mg+10mg 30tk; 20mg+10mg 10tk; 20mg+10mg 90tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivakaftoor - tsüstiline fibroos - muud hingamisteede tooted - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - telmisartaan - tablett - 80mg 98tk; 80mg 84tk; 80mg 100tk; 80mg 14tk; 80mg 56tk; 80mg 7tk; 80mg 90tk; 80mg 60tk; 80mg 28tk

Eesti - eesti - Ravimiamet

ranbaxy uk ltd. - memantiin - õhukese polümeerikattega tablett - 20mg 60tk; 20mg 30tk; 20mg 50tk; 20mg 98tk; 20mg 28tk; 20mg 42tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - kandesartaan - tablett - 8mg 28tk; 8mg 50tk